Cutaneous larva migrans

Summary

Cutaneous larva migrans (MONDO:0018500) is a disease. A subtype of parasitic infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide) [Orphanet-validated]

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	cutaneous larva migrans
Mondo ID	MONDO:0018500
MeSH	D007815
Orphanet	423717
ICD-11	657025682
SNOMED CT	19362000
UMLS	C0546999
MedGen	107487
GARD	0001629
Is cancer (heuristic)	no

Also known as: CLM · creeping eruption · dew itch · ground itch

Disease family

This is a subtype of parasitic infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › parasitic infectious disease › cutaneous larva migrans

Related subtypes (16): parasitic Ichthyosporea infectious disease, protozoa infectious disease, helminthiasis, coccidioidomycosis, cryptococcosis, microsporidiosis, Strongylida infectious disease, distomatosis, parasitic myositis, demodicidosis, amoebiasis due to Entamoeba histolytica, amoebiasis due to free-living amoebae, parasitic eye infection, parasitic intestinal disorder, parasitemia, parasitic skin disorder

Subtypes (1): larva migrans, visceral

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.